Piper Sandler Maintains Overweight on Crescent Biopharma, Lowers Price Target to $32

Benzinga · 19h ago
Piper Sandler analyst Biren Amin maintains Crescent Biopharma (NASDAQ:CBIO) with a Overweight and lowers the price target from $35 to $32.